Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of drug repurposing candidates for the treatment of anxiety: A genetic approach.

Psychiatry research - 1 Aug 2023

Woodward Damian J, Thorp Jackson G, Akosile Wole, Ong Jue-Sheng, Gamazon Eric R, Derks Eske M, Gerring Zachary F

Abstract excerpt

Anxiety disorders are a group of prevalent and heritable neuropsychiatric diseases. We previously conducted a genome-wide association study (GWAS) which identified genomic loci associated with anxiety; however, the biological consequences underlying the genetic associations are largely unknown. Integrating GWAS and functional genomic data may improve our understanding of the genetic effects on intermediate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anxiety
Share to Anxiety Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Repositioning

Share to Genetic Predisposition to Disease

Share to Genome-Wide Association Study

Share to Polymorphism, Single Nucleotide

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 37473490
DOI: 10.1016/j.psychres.2023.115343
PMCID: PMC10493169

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of drug repurposing candidates for the treatment of anxiety: A genetic approach.PMID 37473490Read ↗

Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds.Semantic proximity Read ↗

Advancing the use of genome-wide association studies for drug repurposing.Semantic proximity Read ↗

Using genome-wide association results to identify drug repurposing candidatesSemantic proximity Read ↗

Identifying drug targets for neurological and psychiatric disease via genetics and the brain transcriptome.Semantic proximity Read ↗

Genetically informed drug target prioritisation and repurposing for major depressive disorderSemantic proximity Read ↗

When GWAS meets the Connectivity Map: drug repositioning for seven psychiatric disordersSemantic proximity Read ↗

Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders.Semantic proximity Read ↗

Translating GWAS Findings Into Therapies For Depression And Anxiety Disorders: Drug Repositioning Using Gene-Set Analyses Reveals Enrichment Of Psychiatric Drug ClassesSemantic proximity Read ↗

Linking GWAS to pharmacological treatments for psychiatric disordersSemantic proximity Read ↗

A computational genetic- and transcriptomics-based study nominates drug repurposing candidates for the treatment of chronic painSemantic proximity Read ↗

Pharmaceutical Repurposing Strategies for Metabolic Disorders: Insights from Mendelian Randomization StudiesSemantic proximity Read ↗

Psychiatric genome-wide association study enrichment shows promise for future psychopharmaceutical discoveriesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.